Recently published Nephrotic Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, nephrotic syndrome emerging drugs, market share of individual ...
2d
Ligand Pharmaceuticals: The Bull Case Is A Biotech ARM, The Bear Case Is Just Another Royalty Trust
Ligand Pharma (LGND) stock jumped in the final week of June, but the proximate cause was the pricing of $625M of convertible ...
Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300 over six years. Read why LGND stock is a Buy.
Detailed price information for Definium Therapeutics Inc (DFTX-Q) from The Globe and Mail including charting and trades.
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency's (EMA) ...
BeOne Medicines (HKEX: 06160) has reported positive topline results from the Phase III MANGROVE trial, showing that Brukinsa (zanubrutinib) plus rituximab significantly outperformed standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results